• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease.

作者信息

Singh Dave, Bafadhel Mona, Brightling Christopher E, Sciurba Frank C, Curtis Jeffrey L, Martinez Fernando J, Pasquale Cara B, Merrill Debora D, Metzdorf Norbert, Petruzzelli Stefano, Tal-Singer Ruth, Compton Christopher, Rennard Stephen, Martin Ubaldo J

机构信息

Division of Infection, Immunity, and Respiratory Medicine, University of Manchester, Manchester University National Health Service Hospital Trust, Manchester, United Kingdom.

Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

出版信息

Am J Respir Crit Care Med. 2020 Sep 1;202(5):660-671. doi: 10.1164/rccm.201912-2384PP.

DOI:10.1164/rccm.201912-2384PP
PMID:32186896
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7462391/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94ca/7462391/aa129e7bbb9e/rccm.201912-2384PPf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94ca/7462391/e6742dba7775/rccm.201912-2384PPf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94ca/7462391/aa129e7bbb9e/rccm.201912-2384PPf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94ca/7462391/e6742dba7775/rccm.201912-2384PPf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94ca/7462391/aa129e7bbb9e/rccm.201912-2384PPf2.jpg

相似文献

1
Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病临床试验中的血液嗜酸性粒细胞计数
Am J Respir Crit Care Med. 2020 Sep 1;202(5):660-671. doi: 10.1164/rccm.201912-2384PP.
2
Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease.慢性阻塞性肺疾病中血液与支气管黏膜下嗜酸性粒细胞增多及网状基底膜增厚之间的关系
Respirology. 2015 May;20(4):667-70. doi: 10.1111/resp.12475. Epub 2015 Jan 27.
3
The stability of blood Eosinophils in chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者血液中嗜酸性粒细胞的稳定性。
Respir Res. 2020 Jan 10;21(1):15. doi: 10.1186/s12931-020-1279-4.
4
The association between blood eosinophil percent and bacterial infection in acute exacerbation of chronic obstructive pulmonary disease.血嗜酸性粒细胞百分比与慢性阻塞性肺疾病急性加重期细菌感染的关系。
Int J Chron Obstruct Pulmon Dis. 2019 May 6;14:953-959. doi: 10.2147/COPD.S197361. eCollection 2019.
5
Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者的血嗜酸性粒细胞计数阈值与加重。
J Allergy Clin Immunol. 2018 Jun;141(6):2037-2047.e10. doi: 10.1016/j.jaci.2018.04.010. Epub 2018 Apr 28.
6
Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.血嗜酸性粒细胞计数与慢性阻塞性肺疾病患者肺炎风险：一项基于患者的荟萃分析。
Lancet Respir Med. 2016 Sep;4(9):731-741. doi: 10.1016/S2213-2600(16)30148-5. Epub 2016 Jul 23.
7
Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD.外周血嗜酸性粒细胞：稳定期慢性阻塞性肺疾病气道嗜酸性粒细胞增多的替代标志物。
Int J Chron Obstruct Pulmon Dis. 2016 Jul 1;11:1495-504. doi: 10.2147/COPD.S100338. eCollection 2016.
8
Using the Peripheral Blood Eosinophil Count to Manage Patients with Chronic Obstructive Pulmonary Disease.利用外周血嗜酸性粒细胞计数管理慢性阻塞性肺疾病患者。
Ann Am Thorac Soc. 2019 Mar;16(3):301-303. doi: 10.1513/AnnalsATS.201810-729PS.
9
Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis.血液嗜酸性粒细胞计数，在后 RCT 和观察性研究中预测吸入性皮质类固醇预防 COPD 加重的有效性标志物：系统评价和荟萃分析。
Respir Res. 2020 Jan 3;21(1):3. doi: 10.1186/s12931-019-1268-7.
10
Stability of blood eosinophils in acute exacerbation of chronic obstructive pulmonary disease and its relationship to clinical outcomes: a prospective cohort study.慢性阻塞性肺疾病急性加重期血液嗜酸性粒细胞的稳定性及其与临床结局的关系：一项前瞻性队列研究。
Respir Res. 2021 Nov 24;22(1):301. doi: 10.1186/s12931-021-01888-5.

引用本文的文献

1
Characteristics and actions in high-risk COPD in unstable patients: The EPOCONSUL audit.不稳定患者中高危慢性阻塞性肺疾病（COPD）的特征与行为：EPOCONSUL审计
PLoS One. 2025 Jul 18;20(7):e0327775. doi: 10.1371/journal.pone.0327775. eCollection 2025.
2
Artificial neural network risk prediction of COPD exacerbations using urine biomarkers.使用尿液生物标志物的慢性阻塞性肺疾病急性加重的人工神经网络风险预测
ERJ Open Res. 2025 Jun 2;11(3). doi: 10.1183/23120541.00797-2024. eCollection 2025 May.
3
Pharmacogenetic Factors Shaping Treatment Outcomes in Chronic Obstructive Pulmonary Disease.

本文引用的文献

1
A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial.在IMPACT试验中，单次血液嗜酸性粒细胞计数测量对于预测ICS治疗反应而言与两次测量效果相当。
Eur Respir J. 2021 Sep 23;58(3). doi: 10.1183/13993003.04522-2020. Print 2021 Sep.
2
The stability of blood Eosinophils in chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者血液中嗜酸性粒细胞的稳定性。
Respir Res. 2020 Jan 10;21(1):15. doi: 10.1186/s12931-020-1279-4.
3
Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis.
影响慢性阻塞性肺疾病治疗效果的药物遗传学因素
Genes (Basel). 2025 Mar 6;16(3):314. doi: 10.3390/genes16030314.
4
Is Disease Stability an Attainable Chronic Obstructive Pulmonary Disease Treatment Goal?疾病稳定是慢性阻塞性肺疾病可实现的治疗目标吗？
Am J Respir Crit Care Med. 2025 Mar;211(3):452-463. doi: 10.1164/rccm.202406-1254CI.
5
Inflammatory profile of eosinophils in asthma-COPD overlap and eosinophilic COPD: a multi-omics study.哮喘-慢阻肺重叠和嗜酸性 COPD 中嗜酸性粒细胞的炎症特征：一项多组学研究。
Front Immunol. 2024 Oct 8;15:1445769. doi: 10.3389/fimmu.2024.1445769. eCollection 2024.
6
Design of the SPIROMICS Study of Early COPD Progression: SOURCE Study.慢性阻塞性肺疾病（COPD）早期进展的SPIROMICS研究设计：SOURCE研究
Chronic Obstr Pulm Dis. 2024 Sep 27;11(5):444-459. doi: 10.15326/jcopdf.2023.0490.
7
Lack of Association between Inhaled Corticosteroid Use Based on the Exhaled Nitric Oxide and Acute Exacerbation of Chronic Obstructive Pulmonary Disease.基于呼出一氧化氮的吸入性糖皮质激素使用与慢性阻塞性肺疾病急性加重之间无关联。
Tuberc Respir Dis (Seoul). 2024 Jul;87(3):329-337. doi: 10.4046/trd.2023.0175. Epub 2024 Mar 5.
8
[Effects of type 2 inflammation on bronchodilator responsiveness of large and small airways in chronic obstructive pulmonary disease].[2型炎症对慢性阻塞性肺疾病大、小气道支气管扩张剂反应性的影响]
Nan Fang Yi Ke Da Xue Xue Bao. 2024 Jan 20;44(1):93-99. doi: 10.12122/j.issn.1673-4254.2024.01.11.
9
The genetic etiology of body fluids on chronic obstructive airways disease.慢性阻塞性气道疾病体液的遗传病因学。
Respir Res. 2024 Jan 19;25(1):46. doi: 10.1186/s12931-023-02661-6.
10
Optimizing inhaled corticosteroid use in patients with chronic obstructive pulmonary disease: assessing blood eosinophils, neutrophil-to-lymphocyte ratio, and mortality outcomes in US adults.优化慢性阻塞性肺疾病患者吸入性皮质类固醇的使用：评估美国成年人血液嗜酸性粒细胞、中性粒细胞与淋巴细胞比值和死亡率结局。
Front Immunol. 2023 Nov 15;14:1230766. doi: 10.3389/fimmu.2023.1230766. eCollection 2023.
吸入性类固醇、循环嗜酸性粒细胞、慢性气道感染与慢性阻塞性肺疾病肺炎风险：网络分析。
Am J Respir Crit Care Med. 2020 May 1;201(9):1078-1085. doi: 10.1164/rccm.201908-1550OC.
4
Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.预测慢性阻塞性肺疾病患者对贝那鲁肽的反应：GALATHEA 和 TERRANOVA 研究分析。
Lancet Respir Med. 2020 Feb;8(2):158-170. doi: 10.1016/S2213-2600(19)30338-8. Epub 2019 Sep 28.
5
Do blood eosinophils strictly reflect airway inflammation in COPD? Comparison with asthmatic patients.血液嗜酸性粒细胞是否严格反映 COPD 中的气道炎症？与哮喘患者的比较。
Respir Res. 2019 Jul 10;20(1):145. doi: 10.1186/s12931-019-1111-1.
6
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.血液嗜酸性粒细胞与慢性阻塞性肺疾病三联和双联治疗反应：IMPACT 试验分析。
Lancet Respir Med. 2019 Sep;7(9):745-756. doi: 10.1016/S2213-2600(19)30190-0. Epub 2019 Jul 4.
7
Blood eosinophil counts in COPD patients compared to controls.慢性阻塞性肺疾病（COPD）患者与对照组的血液嗜酸性粒细胞计数比较。
Eur Respir J. 2019 Oct 24;54(4). doi: 10.1183/13993003.00633-2019. Print 2019 Oct.
8
Benralizumab for the Prevention of COPD Exacerbations.贝那鲁肽治疗 COPD 恶化
N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20.
9
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.全球慢性阻塞性肺疾病诊断、管理和预防策略：GOLD 科学委员会报告 2019.
Eur Respir J. 2019 May 18;53(5). doi: 10.1183/13993003.00164-2019. Print 2019 May.
10
Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation.慢性阻塞性肺疾病生物标志物及其解读。
Am J Respir Crit Care Med. 2019 May 15;199(10):1195-1204. doi: 10.1164/rccm.201810-1860SO.